International Clinical Trial: A phase II/III randomized, observer-blind, active-controlled study to compare non-inferior immunogenicity of a combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine to a licensed DTaP based vaccine (non-recombinant), when administered to healthy toddlers aged of 15-36 months old

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (TCTR20200325002) titled 'A phase II/III randomized, observer-blind, active-controlled study to compare non-inferior immunogenicity of a combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine to a licensed DTaP based vaccine (non-recombinant), when administered to healthy toddlers aged of 15-36 months old' on March 25, 2020.

Study Type: Interventional

Study Design: Randomized

Primary Sponsor: Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol Uiversity

Condition: Pertussis Pertussis Pertussis

Intervention: Acellular pertussis (DTaP) vaccine given intramuscularly as a single dose (0.5 ml) on day 0,...